Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a series of topoisomerase inhibiting small molecules with anticancer activity. These molecules possess comparable activity and selectivity to doxorubicin, a common cancer chemotherapy drug, across a range of cancer cell lines. These small molecules are a promising alternative to cardiotoxicity producing doxorubicin as a cancer chemotherapy drug. These molecules are also useful as broad-spectrum antibiotics capable of treating resistant bacteria strains (minimum inhibitory concentrations as low as 0.5 micrograms/mL for S. aureus and E. coli).
